Novel 4-arylaminoquinazoline derivatives with (E)-propen-1-yl moiety as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells

Eur J Med Chem. 2017 Sep 29:138:689-697. doi: 10.1016/j.ejmech.2017.06.023.

Li Chen ¹, Yaling Zhang ¹, Juan Liu ¹, Weijia Wang ¹, Xiabing Li ², Lijun Zhao ¹, Wei Wang ¹, Baolin Li ³

Affiliations

1 Key Laboratory of the Ministry of Education for Medicinal Resources and Natural Pharmaceutical Chemistry, National Engineering Laboratory for Resource Development of Endangered Crude Drugs in Northwest of China, School of Chemistry & Chemical Engineering, Shaanxi Normal University, Xi'an 710062, PR China.
2 Key Laboratory of the Ministry of Education for Medicinal Resources and Natural Pharmaceutical Chemistry, National Engineering Laboratory for Resource Development of Endangered Crude Drugs in Northwest of China, School of Chemistry & Chemical Engineering, Shaanxi Normal University, Xi'an 710062, PR China. Electronic address: xiabingli@snnu.edu.cn.
3 Key Laboratory of the Ministry of Education for Medicinal Resources and Natural Pharmaceutical Chemistry, National Engineering Laboratory for Resource Development of Endangered Crude Drugs in Northwest of China, School of Chemistry & Chemical Engineering, Shaanxi Normal University, Xi'an 710062, PR China. Electronic address: baolinli@snnu.edu.cn.

PMID: 28711703 DOI: 10.1016/j.ejmech.2017.06.023

Abstract

A series of novel 4-anilinoquinazoline derivatives with (E)-propen-1-yl moiety were designed, synthesized and evaluated for biological activities in vitro. Most compounds exhibited highly antiproliferative activities against all tested tumor cell lines including A431, A549, NCI-H1975 and SW480 cells. Especially, compound 6e not only presented strong antiproliferative activities against the tested four tumor cell lines (IC₅₀ of 1.35, 8.83, 5.53 and 6.08 μM, respectively) which expressed wild type or L858R/T790M double mutant epidermal growth factor receptor (EGFR), but also showed potent inhibitory activity against wild type EGFR (IC₅₀ = 20.72 nM). The result of molecular docking with EGFR suggested the binding mode of 6e was similar to gefitinib, but different from lapatinib. Additionally, western blot analysis showed that 6e inhibited the phosphorylation of EGFR and its downstream signaling proteins in lung Cancer cells. The work could be very useful starting point for developing a new series of tyrosine kinase inhibitors targeting EGFR.

Keywords

(E)-propen-1-yl moiety; 4-Anilinoquinazoline; Antiproliferative activities; Epidermal growth factor receptor; Tyrosine kinase inhibitors.

Name
Email *

	Sorry, but the email address you supplied was invalid.